[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
October 25, 1985


JAMA. 1985;254(16):2283-2286. doi:10.1001/jama.1985.03360160115027

For the past 18 months, considerable attention has been focused on the use of retinoids, topical minoxidil, cultured epidermal cells, and nonsteroidal antiinflammatory drugs (NSAIDs) to treat a variety of skin diseases. The therapeutic uses and toxicity of the retinoids continue to dominate the attention of dermatologists. Application of minoxidil appears to be a relatively safe and effective way to induce hair growth in some individuals with androgenetic alopecia or alopecia areata. The dramatic effectiveness of cultured epidermal cells in covering burn wounds in two severely burned children highlighted a decade of achievement in the ability to grow human epidermal cells in culture.1 Nonsteroidal anti-inflammatory drugs, which alter arachidonic acid metabolism, may be useful in treating hyperproliferative and inflammatory skin diseases, but produce varied adverse cutaneous reactions.

Since the introduction of isotretinoin (13-cis-retinoic acid) into the US market in September 1982, for the treatment of nodulocystic acne